Belmond Ltd. (NYSE:BEL)
Belmond is a global collection of exceptional hotel and luxury travel adventures in some of the world’s most inspiring and enriching destinations. Established almost 40 years ago with the acquisition of Belmond Hotel Cipriani in Venice, the Company owns and operates unique and distinctive hotel, rail and river cruise experiences in many of the world’s most celebrated destinations. From city landmarks to intimate resorts, the collection includes Belmond Grand Hotel Europe, St. Petersburg; Belmond Copacabana Palace, Rio de Janeiro; Belmond Maroma Resort & Spa, Riviera Maya; and Belmond El Encanto, Santa Barbara. Belmond also encompasses safaris, six luxury tourist trains including the Venice Simplon-Orient-Express, three river cruises and ’21’, one of New York’s most storied restaurants.
Belmond Ltd. (NYSE:BEL)’s Financial Overview
Belmond Ltd. (NYSE) surged 0.04% yesterday to close its trading session at $24.92. The company has 1 year Price Target of $21.67. Belmond Ltd. has 52-Week high of $25.38 and 52-Week Low of $10.3. The stock touched its 52-Week High on 25.38 and 52-Week Low on 10.30. The stock traded with the volume of 668047 shares yesterday. The firm shows the market capitalization of $3.02 Billion.
Belmond Ltd. (NYSE) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $0.34/share against the analyst consensus estimate of $0.28/share. The difference between the actual and expected EPS is $0.06 a share with a surprise factor of 21.4%.
The firm is trading with SMA20 of 0.14 Percent, SMA50 of 6.54 Percent and SMA200 of 49.12 percent. Belmond Ltd. has P/S value of 5.28 while its P/B value stands at 3.8. Similarly, the company has Return on Assets of -2 percent, Return on Equity of -4.9 percent and Return on Investment of -1.3 Percent. The company shows Gross Margin and Operating Margin of 55.1 percent and 1.2 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 3.3 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 2 analysts offering 12-month price forecasts for Belmond Ltd have a median target of 25.00, with a high estimate of 25.00 and a low estimate of 25.00. The median estimate represents a +0.32% increase from the last price of 24.92.
Belmond Ltd. is expected* to report earnings on 02/27/2019 after market close. The report will be for the fiscal Quarter ending Dec 2018. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.05. The reported EPS for the same quarter last year was $-0.06.
Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts.
Ocular Therapeutix, Inc. (NASDAQ:OCUL)’s Financial Outlook
The 7 analysts offering 12-month price forecasts for Ocular Therapeutix Inc have a median target of 13.00, with a high estimate of 24.00 and a low estimate of 11.00. The median estimate represents a +264.15% increase from the last price of 3.57.
Ocular Therapeutix, Inc. is estimated to report earnings on 03/14/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.37. The reported EPS for the same quarter last year was $-0.44.
According to Zacks Investment Research, Ocular Therapeutix, Inc. has a Consensus Recommendation of 1. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock surged 0.85% and closed its last trading session at $3.57. The company has the market capitalization of $150.01 Million. The stock has 52-week high of $8.28 and 52-Week low of $3.46. The firm touched its 52-Week high on 8.28 and 52-Week low on 3.46. The company has volume of 192072 shares. The company has a total of 42.02 Million shares outstanding.
Ocular Therapeutix, Inc. (NASDAQ) in the last quarter reported its actual EPS of $-0.38/share where the analyst estimated EPS was $-0.38/share. The difference between the actual and Estimated EPS is $0. This shows a surprise factor of 0 percent.
The company has YTD performance of -10.3 percent. Beta for Ocular Therapeutix, Inc. stands at 1.8 while its ATR (average true range) is 0.19. The company has Weekly Volatility of 4.09%% and Monthly Volatility of 4.72%%.
Ocular Therapeutix, Inc. has distance from 20-day Simple Moving Average (SMA20) of -5.62%, Distance from 50-Day Simple Moving Average of -19.5 percent and Distance from 200-Day Simple Moving Average of -39.28%.
The Company currently has ROA (Return on Assets) of -81.6 percent, Return on Equity (ROE) of -133.7 Percent and Return on Investment (ROI) of -140.4% with Gross margin of 76.6 percent and Operating & Profit margin of 0% and 0% respectively.